The Nomination Committee consists of
The task of the Nomination Committee is to prepare and present proposals for the number of board members to be elected by the AGM, the election of a chairman and other members of the board, board fees and, if any, remuneration for committee work, election of a chairman to the Annual General Meeting, election of auditors (if applicable) and auditors' fees (if applicable) and proposals for rules for the appointment of a nomination committee for the Annual General Meeting 2024.
The Annual General Meeting of
For further information, please contact:
E-mail: jacob.gunterberg@vicorepharma.com
This information was submitted for publication on
About
Vicore is an innovative Swedish clinical-stage pharmaceutical company dedicated to creating life-changing treatments in diseases where the Angiotensin II type 2 receptor (AT2R) has a central protective role. The company currently has four development programs, VP01, VP02, VP03 and VP04. VP01 aims to develop the substance C21 for the treatment of idiopathic pulmonary fibrosis (IPF) and pulmonary artery hypertension (PAH). VP02 is a new formulation and delivery route of thalidomide and focuses on the underlying disease and the severe cough associated with IPF. In the VP03 program new AT2 receptor agonists are developed. VP04 is a clinically validated digital therapeutic in development for IPF patients.
The company's shares (VICO) are listed on Nasdaq Stockholm's main market. For more information, see www.vicorepharma.com.
https://news.cision.com/vicore-pharma-holding-ab/r/vicore-announces-the-nomination-committee-for-the-2023-annual-general-meeting,c3651150
https://mb.cision.com/Main/15668/3651150/1640808.pdf
(c) 2022 Cision. All rights reserved., source